Advanced search
Publication Cover
mAbs Volume 16, 2024 - Issue 1
Submit an article Journal homepage
3,192
Views
0
CrossRef citations to date
0
Altmetric
Report

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers

Ammelie Svea Bojea Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel, GermanyView further author information
,
Lukas Pekarb Antibody Discovery & Protein Engineering, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
,
Katharina Koepc Drug Metabolism and Pharmacokinetics, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
,
Britta Lipinskib Antibody Discovery & Protein Engineering, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
,
Brian Rabinovichd Department of Oncology and Immuno-Oncology, EMD Serono Research & Development Institute Inc, 45A Middlesex Turnpike, Billerica, MA, USAView further author information
,
Andreas Eversb Antibody Discovery & Protein Engineering, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
,
Carina Lynn Gehlerta Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel, GermanyView further author information
,
Steffen Krohna Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel, GermanyView further author information
,
Yanping Xiaod Department of Oncology and Immuno-Oncology, EMD Serono Research & Development Institute Inc, 45A Middlesex Turnpike, Billerica, MA, USAView further author information
,
Simon Krahb Antibody Discovery & Protein Engineering, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
,
Rinat Zaynagetdinovd Department of Oncology and Immuno-Oncology, EMD Serono Research & Development Institute Inc, 45A Middlesex Turnpike, Billerica, MA, USAView further author information
,
Lars Toleikise Early Protein Supply & Characterization, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
,
Sven Poetzschf Strategic Innovation, Merck Healthcare KGaA, Darmstadt, GermanyView further author information
,
Matthias Peippa Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel, GermanyView further author information
,
Stefan Zielonkab Antibody Discovery & Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany;g Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4649-2843View further author information
ORCID Icon &
Katja Klausza Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Medical Center Schleswig-Holstein and University of Kiel, Kiel, GermanyCorrespondence[email protected]
View further author information
 show all
Article: 2315640 | Received 09 Jun 2023, Accepted 02 Feb 2024, Published online: 19 Feb 2024

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.